NASDAQ:ARDS - Aridis Pharmaceuticals Stock Price, Forecast & News

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) posted its earnings results on Wednesday, November, 13th. The company reported ($0.87) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.54. View Aridis Pharmaceuticals' Earnings History.

Aridis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Aridis Pharmaceuticals.

5 brokers have issued 1-year price targets for Aridis Pharmaceuticals' stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $17.40 in the next year. This suggests a possible upside of 135.5% from the stock's current price. View Analyst Price Targets for Aridis Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aridis Pharmaceuticals.

News stories about ARDS stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aridis Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Aridis Pharmaceuticals.

Aridis Pharmaceuticals saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 53,400 shares, an increase of 67.4% from the January 15th total of 31,900 shares. Based on an average daily volume of 17,300 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.0% of the company's shares are short sold. View Aridis Pharmaceuticals' Current Options Chain.

Some companies that are related to Aridis Pharmaceuticals include VBI Vaccines (VBIV), Seres Therapeutics (MCRB), Avadel Pharmaceuticals (AVDL), IVERIC bio (ISEE), Hookipa Pharma (HOOK), Ocular Therapeutix (OCUL), Geron (GERN), MEI Pharma (MEIP), BIOFRONTERA AG/ADR (BFRA), Kalvista Pharmaceuticals (KALV), XOMA (XOMA), Protagonist Therapeutics (PTGX), MediciNova (MNOV), Sol Gel Technologies (SLGL) and Kala Pharmaceuticals (KALA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Tandem Diabetes Care (TNDM), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Krystal Biotech (KRYS) and Lexicon Pharmaceuticals (LXRX).

(ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDS stock can currently be purchased for approximately $7.39.

Aridis Pharmaceuticals has a market capitalization of $65.84 million and generates $2.76 million in revenue each year. The company earns $-22,100,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. Aridis Pharmaceuticals employs 23 workers across the globe.View Additional Information About Aridis Pharmaceuticals.

The official website for Aridis Pharmaceuticals is http://www.aridispharma.com/.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct., San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected]